Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-101 + HT-102 injections in chronic hepatitis B patients on nucleos(t)ide analogues
ChiCTR2600129961Phase 2Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HT-101 and HT-102 in Chronic Hepatitis B (CHB) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Functional cure at week 60. Started Aug 2026; status: completed.
02
Drugs
HT-101HT-102
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2600129961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129961.